EUR 0.23
(-0.43%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 25.15 Million EUR | -0.57% |
2022 | 25.29 Million EUR | 19.55% |
2021 | 21.16 Million EUR | 57.57% |
2020 | 13.42 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 FY | 25.15 Million EUR | -0.57% |
2023 Q4 | 25.15 Million EUR | 0.0% |
2023 Q2 | 18.38 Million EUR | 2.39% |
2023 Q1 | 17.95 Million EUR | -29.04% |
2022 Q4 | 25.29 Million EUR | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
European Medical Solutions | 12.71 Million EUR | -97.806% |
FERMENTALG | 14.33 Million EUR | -75.429% |
argenx SE | 15.35 Million EUR | -63.821% |
BioSenic S.A. | 15.57 Million EUR | -61.517% |
Celyad Oncology SA | 902 Thousand EUR | -2688.581% |
Hyloris Pharmaceuticals SA | 344 Thousand EUR | -7211.919% |
Onward Medical N.V. | 16.3 Million EUR | -54.256% |
Oxurion NV | 117 Thousand EUR | -21398.291% |
PHAXIAM Therapeutics S.A. | 7.03 Million EUR | -257.795% |
Financière de Tubize SA | - EUR | -Infinity% |
UCB SA | 2.87 Billion EUR | 99.126% |